Cepheid recalled 9,880 units of the Xpert MTB/RIF testing device on November 5, 2025. Product testing failed to meet expected stability criteria, leading to potential inaccuracies. Healthcare providers and patients must stop using the device immediately.
Product testing did not meet expected stability criteria.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Cepheid or your healthcare provider for instructions. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is the Xpert MTB/RIF with Model Number GXMTB/RIF-US-10. It was distributed nationwide in the U.S. and Puerto Rico. The device has a UDI-DI of 07332940000912, batch number 1000812229, lot number 41302, and an expiration date of February 2, 2025.
The device failed stability testing, which raises concerns about its reliability in diagnosing tuberculosis. This failure could lead to misdiagnosis or delayed treatment for patients.
There are no reported injuries or incidents related to this recall. The stability issue is a preventative measure to ensure patient safety.
Patients and healthcare providers should stop using the Xpert MTB/RIF device immediately. Contact Cepheid or your healthcare provider for further instructions and follow the recall instructions provided.
For more information, contact Cepheid at their customer service number or visit their website. The recall notification was sent via letter to affected users.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.